

SECTION 9.0 – REPOSITORY SPECIMEN INVENTORY

9.1. Annual Visit (Core) Samples Available – Summary Tables

9.1.1. Annual Visit Serum

9.1.2. Annual Visit Plasma, EDTA and Citrate Tubes

9.1.3. Annual Visit Urine

9.2. Daily Hormone Study (DHS) Samples Available – Summary Tables

9.2.1. DHS Urine

9.2.2. DHS Serum

9.3. Genetic Materials

9.3.1. Extracted, Diluted DNA

9.3.2. EBV-Transformed Cells

9.3.3. Buccal Cells

9.3.4. The SWAN Population Contributing Genetic Materials

9.4. Costs Associated with Obtaining Repository Biospecimens

9.0 REPOSITORY SPECIMEN INVENTORY

The following tables summarize the specimens available through the SWAN Repository.

9.1. Annual Visit (Core) Samples

The table below shows the number of SWAN participants with data collected at each completed follow-up visit* and the number with Core serum/plasma/urine in the Repository.

	Base -line	V 01	V 02	V 03	V 04	V 05	V 06	V 07	V 08	V 09	V 10	V 12	V 13
In Core Study	3302	2867	2725	2694	2658	2604	2441	2320	2274	2246	2239	2399	2338
In Core Study with Repository specimens	3276	2773	2528	2357	2232	2174	2085	2048	1462	1994	1908	2006	1947
% in Core Study with Repository specimens	99%	97%	93%	87%	84%	83%	85%	88%	64%	89%	85%	84%	83%

*excludes refusals, persons active but not available to participate that visit, and the deceased. There are no visit 06-10 data from the New Jersey site due to a hiatus in data collection at that site. Specimens are not collected from participants participating by telephone interview, who at Visit 8 participated in the mailed protocol option. Visits 11 and 14 were interim years; therefore no Repository specimens were collected.

9.1.1. Available Serum from SWAN Core, as of **MARCH 1, 2016**

Visit	Material type	Vial status	Vial Count	Women with Serum	Avg Vials Per Woman	Avg Vial Volume (mL)
00	Serum	In	13,903	3269	4	1.1
01	Serum	In	24,490	2723	9	0.59
02	Serum	In	40,662	2518	13	0.58
03	Serum	In	34,313	2346	14	0.58
04	Serum	In	31,534	2278	12	0.60
05	Serum	In	30,843	2188	12	0.62
06	Serum	In	30,099	2096	13	0.63
07	Serum	In	31,026	2064	14	0.61
08	Serum	In	24,161	1471	15	0.64
09	Serum	In	29,884	2046	14	0.65
10	Serum	In	32,364	1916	14	0.61
12	Serum	In	24,619	1995	12	0.52
13	Serum	In	30,370	1900	16	0.59
15	Serum	In	4,841	725	7	0.49

Total serum vials 383,109

9.1.2. Available Plasma (EDTA and Citrated) from SWAN Core, as of **MARCH 1, 2016**

Visit	Material type	Vial status	Vial Count	Women with Plasma	Avg Vials Per Woman	Avg Vial Volume (mL)
00	EDTA PLASMA	In	3179	3151	1	1.3
01*	EDTA PLASMA	In	2796	2701	1	1.0
02*	EDTA PLASMA	In	6130	2229	3	1.0
03*	EDTA PLASMA	In	2242	2231	1	1.1
04*	EDTA PLASMA	In	4378	2262	2	1.0
05*	EDTA PLASMA	In	2242	2126	1	1.0
06*	EDTA PLASMA	In	4001	2066	2	1.0
07*	EDTA PLASMA	In	2770	1878	1	1.0
08*	EDTA PLASMA	In	4059	1370	3	1.0
09*	EDTA PLASMA	In	3638	1833	3	1.0
10*	EDTA PLASMA	In	3899	1858	3	1.0
12	EDTA PLASMA	In	2992	1522	2	1.0
13	EDTA PLASMA	In	3568	1812	2	1.0
15	EDTA PLASMA	In	5084	739	7	0.5

Total EDTA plasma vials 50,978

*All Repository EDTA plasma from Visit 01-10 are samples recovered from MRL.

Visit	Material type	Vial status	Vial Count	Women with Plasma	Avg Vials Per Woman	Avg Vial Volumes (mL)
00	Citrate PLASMA	In	3183	3167	1	1.2
01	Citrate PLASMA	In	9534	2697	4	0.9
02	Citrate PLASMA	In	9275	2492	4	0.6
03	Citrate PLASMA	In	6765	2326	3	0.5
04	Citrate PLASMA	In	6344	2158	3	0.5
05	Citrate PLASMA	In	6218	2089	3	0.5
06	Citrate PLASMA	In	5930	2021	3	0.5
07	Citrate PLASMA	In	5827	1983	3	0.5
08	Citrate PLASMA	In	5438	1449	4	0.6
09	Citrate PLASMA	In	7453	1970	4	0.6
10	Citrate PLASMA	In	7389	1890	4	0.6
12	Citrate PLASMA	In	5963	1979	3	0.5
13	Citrate PLASMA	In	5398	1847	3	0.5
15	Citrate PLASMA	In	2195	744	3	0.5

Total Citrate plasma vials 86,912

9.1.3. Available Urine from SWAN Core, as of **MARCH 1, 2016**

Visit	Material type	Vial status	Vial Count	Women with Urine	Avg Vials Per Woman	Avg Volume/ Vial (mL)
00	Urine	In	5345	2375	2	0.95
01	Urine	In	8199	2063	4	1.00
02	Urine	In	12551	1967	6	0.51
03	Urine	In	14555	1864	8	0.63
04	Urine	In	13946	1814	8	0.68
05	Urine	In	12323	1770	7	0.70
06	Urine	In	13911	1790	8	0.69
07	Urine	In	13439	1751	8	0.68
08	Urine	In	9556	1251	8	0.69
09	Urine	In	14654	1655	9	0.61
10	Urine	In	14969	1698	9	0.59
12	Urine	In	13089	1639	8	0.50
13	Urine	In	12563	1573	8	0.50
15	Urine	In	1843	463	4	2.00

Total urine vials 160,943

9.2. Daily Hormone Study (DHS) Samples, collected 1997-2008

9.2.1. DHS Urine

Visit	Material Type	Vials In	Women with DHS Urine	Avg large vials per woman (5mL)	Avg <u>aliquoted</u> tubes per woman (0.5mL)
H1	Urine	280,276	884	29	291 (10/day)
H2	Urine	240,882	727	31	306 (10/day)
H3	Urine	202,897	645	32	320 (10/day)
H4	Urine	128,094	539	44	317 (7/day)
H5	Urine	88,988	403	35	326 (9/day)
H6	Urine	60,754	271	38	417 (11/day)
H7	Urine	8,274	208	40	<i>not aliquoted</i>
H8	Urine	6,624	171	39	<i>not aliquoted</i>
H9	Urine	4,534	124	37	<i>not aliquoted</i>

1,021,323

9.2.2. DHS Serum

Visit	Material Type	Vials In	Women with DHS Serum	Avg Vial Volume (mL)
H1	Serum	4,652	888	1.8
H2	Serum	3,771	725	2.0
H3	Serum	3,419	644	1.8
H4	Serum	2,417	522	1.6
H5	Serum	2,022	401	0.5
H6	Serum	843	263	0.5
H7	Serum	1,163	207	0.5
H8	Serum	876	166	0.5
H9	Serum	592	119	0.5
H10	Serum	342	84	0.5

1,021,323

9.3. Genetic Materials

9.3.1. DNA

The SWAN Repository offers diluted extracted DNA to the scientific community. The DNA comes from EBV-transformed cells, see processing details in Section 4. The total volume of DNA per stock vial is 5µg. The vials are stored on VP-LN2 (liquid nitrogen vapor).

Because the DNA resource comes from renewable cells, and can be replenished, DNA is not considered Reserved. The number of SWAN participants who have DNA available is 1538.

9.3.2. EBV-Transformed Cells

The Epstein-Barr Virus-transformed, or immortalized, cell lines are also available to the scientific community. (See processing details in Section 4.)

9.3.3. Buccal Cells

The buccal cell samples collected during the special one-time collection are another source of DNA from the SWAN participants.

9.3.4. The SWAN Population with Genetic Materials

1538 women from the SWAN Study population have consented and contributed to the Repository DNA specimen bank. The race/ethnicity breakdown of the contributors is shown below. Note that no New Jersey site samples are included in any of the genetic materials (see comment in section 3.3.1).

DNA Ethnic Breakdown	
BLACK	412
CAUCA	807
CHINE	151
JAPAN	168
TOTAL	1538

9.4. Costs associated with obtaining biospecimens

Cost recovery efforts have been put into place, following directives from NIA (section 7). The following recharge rates apply to specimens released from the SWAN Repository:

SWAN Biospecimen costs

	Serum, Plasma, and Urine	Extracted DNA	Transformed Cell lines
Direct Costs	\$18	\$65	\$148
Indirect Costs	+30%	+30%	+30%

Rates valid through 10/21/2015.

SWAN Application & Data set fees

	Application Processing Fee	Encrypted Data Set Construction Fee
Direct Costs	\$400	\$950
Indirect Costs	+30%	+30%

Rates valid through 10/21/2015.

These prices are based on actual costs accrued in the collection, storage, retrieval and distribution of SWAN samples. An official quote will be provided to individual applicants when the final sample selection is defined.

Ver032316